Latest Financials News

McMillan Shakespeare Limited reported a 14.1% rise in statutory net profit for FY25, marking the completion of its transformative Simply Stronger program that enhanced digital offerings and customer reach.

The Federal Court of Australia has dismissed Harvey Norman’s appeal against prior legal declarations, setting the stage for an upcoming penalty hearing that could impact the retailer’s future.

NeuroScientific Biopharmaceuticals reported a $1.85 million loss for FY25, driven by reduced R&D incentives and increased development costs following its acquisition of StemSmart™ technology. The company is advancing clinical programs, including a Special Access Scheme for Crohn’s disease.

McMillan Shakespeare Limited reported a 14.1% rise in statutory net profit after tax to $95.3 million for FY25, alongside a fully franked final dividend of 77 cents per share. The company’s strategic investments in digital platforms and acquisitions underpin its growth trajectory.

Algorae Pharmaceuticals reported a 62% reduction in net loss for FY2025, driven by R&D tax credits and cost efficiencies, while making significant strides in its AI drug discovery platform and therapeutic candidates.

Global X Management (AUS) Limited has announced updated estimated distribution amounts for three of its ETFs listed on the ASX AQUA Market for the period ending 31 August 2025, alongside key dates for investors to note.

PYC Therapeutics reported a 14.5% rise in income to AUD 26.17 million for FY2025 alongside a 33.3% increase in net loss, while increasing its stake in Vision Pharma to 97.1%. The auditor flagged material uncertainty over the company’s ability to continue as a going concern.

Brazilian Critical Minerals Ltd has converted a significant portion of its outstanding debt into equity, issuing over 120 million shares to a key investor, while also raising a modest $50,000 through a new share placement to support working capital.

Harris Technology Group reported a 17% revenue decline for FY25 but improved its net loss by nearly 32%, driven by a pivot towards higher-margin refurbished IT products and tighter inventory management.

Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.

Mad Paws Holdings reported a 14% revenue increase and improved EBITDA margins in FY25, while preparing to sell its marketplace business to Rover Group and exit e-commerce operations.

Mad Paws Holdings reported a $12.27 million loss for FY25, deepening from last year, as it divests its Pet Chemist business and agrees to a $62 million acquisition by Rover Group.